BR112014026644A2 - peptídeos de agonistas de par4 - Google Patents
peptídeos de agonistas de par4Info
- Publication number
- BR112014026644A2 BR112014026644A2 BR112014026644A BR112014026644A BR112014026644A2 BR 112014026644 A2 BR112014026644 A2 BR 112014026644A2 BR 112014026644 A BR112014026644 A BR 112014026644A BR 112014026644 A BR112014026644 A BR 112014026644A BR 112014026644 A2 BR112014026644 A2 BR 112014026644A2
- Authority
- BR
- Brazil
- Prior art keywords
- par4
- peptides
- agonist
- agonist peptides
- par4 agonist
- Prior art date
Links
- 102100040853 PRKC apoptosis WT1 regulator protein Human genes 0.000 title abstract 6
- 101710162991 PRKC apoptosis WT1 regulator protein Proteins 0.000 title abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 239000000556 agonist Substances 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 108010079670 alanyl-tyrosyl-prolyl-glycyl-lysyl-phenylalanine Proteins 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 239000004031 partial agonist Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261638577P | 2012-04-26 | 2012-04-26 | |
| US201361781538P | 2013-03-14 | 2013-03-14 | |
| PCT/US2013/037897 WO2013163248A1 (en) | 2012-04-26 | 2013-04-24 | Par4 agonist peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014026644A2 true BR112014026644A2 (pt) | 2017-06-27 |
Family
ID=48289680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014026644A BR112014026644A2 (pt) | 2012-04-26 | 2013-04-24 | peptídeos de agonistas de par4 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8927688B2 (https=) |
| EP (1) | EP2841448A1 (https=) |
| JP (1) | JP2015516983A (https=) |
| CN (1) | CN104411713A (https=) |
| BR (1) | BR112014026644A2 (https=) |
| CA (1) | CA2871640A1 (https=) |
| EA (1) | EA201491959A1 (https=) |
| MX (1) | MX2014012803A (https=) |
| WO (1) | WO2013163248A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2841437T1 (sl) * | 2012-04-26 | 2017-09-29 | Bristol-Myers Squibb Company | Derivati imidazotiadiazola in imidazopirazina kot proteazno aktivirani receptor 4 (PAR4) inhibitorji za zdravljenje agregacije trombocitov |
| US20160274108A1 (en) * | 2013-10-25 | 2016-09-22 | Bristol-Myers Squibb Company | Diagnostic methods for par4 antagonist therapy |
| WO2016134450A1 (en) * | 2015-02-26 | 2016-09-01 | Université de Montréal | Imidazopyridazine and imidazothiadiazole compounds |
| US9789087B2 (en) | 2015-08-03 | 2017-10-17 | Thomas Jefferson University | PAR4 inhibitor therapy for patients with PAR4 polymorphism |
| US9963466B2 (en) | 2016-03-07 | 2018-05-08 | Vanderbilt University | Substituted 5-membered heterocyclic analogs as protease activated receptor 4 (PAR-4) antagonists |
| WO2017184520A1 (en) * | 2016-04-18 | 2017-10-26 | Vanderbilt University | Substituted and fused 6-membered protease activated receptor 4 (par-4) antagonists |
| CN111094300B (zh) * | 2018-01-31 | 2022-09-16 | 江苏恒瑞医药股份有限公司 | 苯并杂芳基类衍生物、其制备方法及其在医药上的应用 |
| CN110218218B (zh) * | 2018-03-01 | 2022-04-08 | 江苏恒瑞医药股份有限公司 | 苯并呋喃类衍生物、其制备方法及其在医药上的应用 |
| CN110627817B (zh) * | 2018-06-25 | 2022-03-29 | 中国药科大学 | 咪唑并环类par4拮抗剂及其医药用途 |
| CN111349105B (zh) * | 2018-12-24 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 苯并呋喃类衍生物、其制备方法及其在医药上的应用 |
| CN111362970A (zh) * | 2018-12-25 | 2020-07-03 | 天津药物研究院有限公司 | 苯并呋喃类衍生物及其制备方法和用途 |
| US12077607B2 (en) | 2021-09-23 | 2024-09-03 | University Of Utah Research Foundation | Functional and therapeutic effects of PAR4 cleavage by cathepsin G |
| CN117285527A (zh) * | 2023-09-25 | 2023-12-26 | 中国药科大学 | 一种噌啉类par4拮抗剂及其医药应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2928079B2 (ja) * | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| AU2001233333A1 (en) * | 2000-02-09 | 2001-08-20 | Zymogenetics Inc. | Par4 peptides and polypeptides |
| WO2001094411A1 (en) * | 2000-06-05 | 2001-12-13 | The Regents Of The University Of California | Peptides modulating protease activated receptors and methods of using same |
| US6387942B2 (en) * | 2000-06-19 | 2002-05-14 | Yung Shin Pharmaceutical Ind. Co. Ltd | Method of treating disorders related to protease-activated receptors-induced cell activation |
| WO2003033515A1 (en) * | 2001-10-15 | 2003-04-24 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of acne vulgaris |
| JP2007527416A (ja) | 2003-10-31 | 2007-09-27 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ペルオキシソーム増殖因子活性化受容体（ｐｐａｒ）二重作動薬として有用なフェノキシ酢酸誘導体 |
-
2013
- 2013-04-24 CA CA2871640A patent/CA2871640A1/en not_active Abandoned
- 2013-04-24 MX MX2014012803A patent/MX2014012803A/es unknown
- 2013-04-24 BR BR112014026644A patent/BR112014026644A2/pt not_active IP Right Cessation
- 2013-04-24 WO PCT/US2013/037897 patent/WO2013163248A1/en not_active Ceased
- 2013-04-24 EA EA201491959A patent/EA201491959A1/ru unknown
- 2013-04-24 CN CN201380034451.0A patent/CN104411713A/zh active Pending
- 2013-04-24 JP JP2015509095A patent/JP2015516983A/ja active Pending
- 2013-04-24 US US13/869,093 patent/US8927688B2/en active Active
- 2013-04-24 EP EP13720698.3A patent/EP2841448A1/en not_active Withdrawn
-
2014
- 2014-11-26 US US14/554,387 patent/US9303065B2/en active Active
-
2016
- 2016-02-23 US US15/051,067 patent/US9605024B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015516983A (ja) | 2015-06-18 |
| US9303065B2 (en) | 2016-04-05 |
| MX2014012803A (es) | 2015-01-15 |
| CN104411713A (zh) | 2015-03-11 |
| US8927688B2 (en) | 2015-01-06 |
| US20160304560A1 (en) | 2016-10-20 |
| US20150158910A1 (en) | 2015-06-11 |
| EA201491959A1 (ru) | 2016-05-31 |
| EP2841448A1 (en) | 2015-03-04 |
| US20130289238A1 (en) | 2013-10-31 |
| CA2871640A1 (en) | 2013-10-31 |
| WO2013163248A1 (en) | 2013-10-31 |
| US9605024B2 (en) | 2017-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014026644A2 (pt) | peptídeos de agonistas de par4 | |
| BRPI0814252A8 (pt) | composição farmacêutica aquosa compreendendo natalizumab | |
| BR112015008311A2 (pt) | conjugados fármaco-proteína | |
| MX2017004559A (es) | Receptores de celulas t. | |
| JOP20200039A1 (ar) | مُستحضر صيدلي يشتمل على hcg مأشوب | |
| BR112018070625A2 (pt) | receptores de células t | |
| BR112012005713A2 (pt) | vacinas direcionadas a célula langerhans. | |
| BR112013005699A2 (pt) | moléculas de ligação a 4-1bb | |
| BR112014008156A2 (pt) | modulação de especificidade de polipeptídeo estruturado | |
| BR112018070637A2 (pt) | receptores de células t | |
| MX366935B (es) | Peptidos intestinales vasoactivos modificados. | |
| MX2013007716A (es) | Sistemas de expresion. | |
| UA118167C2 (uk) | Пептид та його застосування | |
| UA111818C2 (uk) | Антитіло проти csf-1r | |
| BR112012024373A2 (pt) | peptídeos e métodos para sua preparação e uso. | |
| NZ629394A (en) | Synthetic brassica-derived chloroplast transit peptides | |
| AU2011353197A8 (en) | A cross linking polypeptide comprising an hexameric single chain antibody binding MHC-MAGE complex that induces apoptosis | |
| CL2011002660A1 (es) | Anticuerpo anti-receptor de activinas tipo iib (anti-actr-iib); secuencia de polinucleotidos aislados que codifica dicho anticuerpo; vector, celula huesped; composicion farmaceutica; uso para tratar transtornos musculo esqueleticos. | |
| EA033386B1 (ru) | Рекомбинантные иммуногенные полипептиды стеблевого домена гемагглютинина вируса гриппа а и их применение | |
| BR112015022978A8 (pt) | tecnologias de multimerização | |
| BR112014017165A8 (pt) | polipeptídeos de fator quimérico viii e seus usos | |
| BR112012018951A8 (pt) | anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica | |
| MX2014005108A (es) | Constructos de polipeptidos y sus usos. | |
| MX2013007371A (es) | Peptidos de enlace her2 radiomarcados. | |
| BR112014024282A2 (pt) | anticorpos ligantes ao receptor b1 da bradicinina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2515 DE 19-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |